Related posts: The Classification and Diagnosis of Diabetes New Technologies for Insulin Administration and Glucose Monitoring The Role of Community and Specialist Services Transplantation The Role of the Multidisciplinary Team…
Related posts: The Classification and Diagnosis of Diabetes New Technologies for Insulin Administration and Glucose Monitoring The Role of Community and Specialist Services Transplantation The Role of the Multidisciplinary Team…
Related posts: Control of Weight: How Do We Get Fat? New Technologies for Insulin Administration and Glucose Monitoring The Role of Community and Specialist Services Transplantation The Role of the…
Related posts: Control of Weight: How Do We Get Fat? New Technologies for Insulin Administration and Glucose Monitoring The Role of Community and Specialist Services Transplantation The Role of the…
Exenatide clinical efficacy The Phase 3 clinical efficacy studies that have been conducted with exenatide are listed in Table 4.1. Three 30-week, placebo-controlled studies evaluated exenatide (5 µj.g or 10…
In a 52-week active-comparator study, patients not achieving adequate glycaemic control on a metformin dose of at least 1500 mg/day were randomized to sitagliptin 100 mg once daily or glipizide,…
Related posts: The Incretin System Overview of Current Diabetes Management Bariatric Surgery for the Treatment of Type 2 Diabetes Sodium-glucose Cotransporter-2 Inhibitors Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
Figure 6.2 Adjusted mean (95% CI) percent change from baseline in body weight after 12 weeks of dapagliflozin treatment. Reproduced from List et al. (2009) with permission from the American…
Related posts: The Incretin System Overview of Current Diabetes Management Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
Related posts: The Incretin System Overview of Current Diabetes Management Sodium-glucose Cotransporter-2 Inhibitors Epidemiology and Pathogenesis of Type 2 Diabetes Dipeptidyl Peptidase-4 Inhibitors The Incretin Mimetics
